Bains Aman, Cao Yimeng, Kly Sundiata, Wulff Jeremy E, Moffitt Matthew G
Department of Chemistry, University of Victoria , P.O. Box 3065, Victoria, British Columbia V8W 3 V6, Canada.
Mol Pharm. 2017 Aug 7;14(8):2595-2606. doi: 10.1021/acs.molpharmaceut.7b00177. Epub 2017 May 31.
We demonstrate control of multiscale structure and drug delivery function for paclitaxel (PAX)-loaded polycaprolactone-block-poly(ethylene oxide) (PCL-b-PEO) polymeric nanoparticles (PNPs) via synthesis and flow-directed shear processing in a two-phase gas-liquid microfluidic reactor. This strategy takes a page from the engineering of commodity plastics, where processing rather than polymer chemistry provides an experimental handle on properties and function. PNPs formed from copolymers with three different PCL block lengths show sizes, morphologies, and loading efficiencies that depend on both the PCL block length and the microfluidic flow rate. By varying flow rate and comparing with a conventional bulk method of PNP preparation, we show that flow-variable shear processing provides control of PNP sizes and morphologies and enables slower PAX release times (up to 2 weeks) compared to bulk-prepared PNPs. Antiproliferative effects against cultured MCF-7 breast cancer cells were greatest for PNPs formed at an intermediate flow rate, corresponding to small and low-polydispersity spheres formed uniquely at this flow condition. Formation and flow-directed nanoscale shear processing in gas-liquid microfluidic reactors provides a manufacturing platform for drug delivery PNPs that could enable more effective and selective nanomedicines through multiscale structural control.
我们展示了通过在两相气液微流控反应器中进行合成和流动导向剪切处理,对负载紫杉醇(PAX)的聚己内酯-嵌段-聚环氧乙烷(PCL-b-PEO)聚合物纳米颗粒(PNP)的多尺度结构和药物递送功能的控制。该策略借鉴了商品塑料工程的方法,在商品塑料工程中,加工而非聚合物化学为材料的性能和功能提供了实验手段。由三种不同PCL嵌段长度的共聚物形成的PNP,其尺寸、形态和负载效率取决于PCL嵌段长度和微流控流速。通过改变流速并与传统的批量制备PNP的方法进行比较,我们发现流动可变剪切处理能够控制PNP的尺寸和形态,并且与批量制备的PNP相比,能够实现更慢的PAX释放时间(长达2周)。对于在中等流速下形成的PNP,其对培养的MCF-7乳腺癌细胞的抗增殖作用最强,这种流速下形成的是独特的小尺寸、低多分散性球体。气液微流控反应器中的形成和流动导向纳米级剪切处理为药物递送PNP提供了一个制造平台,通过多尺度结构控制,有望实现更有效、更具选择性的纳米药物。